Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	717.21	673	560	434	363.33	351.41
Revenue Growth	17.55%	20.18%	29.03%	19.45%	3.39%	29.66%
Cost of Revenue	121.34	109	77	45	28.32	16.01
Gross Profit	595.88	564	483	389	335.01	335.4
Selling, General & Admin	350.56	349	321	310	278.14	219.98
Research & Development	773.49	750	698	648	705.79	497.15
Total Operating Expenses	1,124	1,099	1,019	958	983.93	717.14
Operating Income	-528.17	-535	-536	-569	-648.92	-381.74
Interest Income	23.38	25	37	27	11.07	1.93
Interest Expense	-76.62	-62	-63	-66	-43.02	-29.42
Other Non-Operating Income (Expense)	-0.37	1	-5	-1	-20.87	-43.75
Total Non-Operating Income (Expense)	-53.61	-36	-31	-40	-52.81	-71.24
Pretax Income	-582.23	-571	-567	-609	-701.73	-452.98
Provision for Income Taxes	3.74	4	2	-2	5.7	1.04
Net Income	-585.97	-575	-569	-607	-707.42	-454.03
Net Income to Common	-585.97	-575	-569	-607	-707.42	-454.03
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	101	99	91	74	70	68
Shares Outstanding (Diluted)	101	99	91	74	70	68
Shares Change	4.19%	8.95%	23.13%	5.13%	3.13%	11.42%
EPS (Basic)	-5.84	-5.83	-6.29	-8.25	-10.12	-6.70
EPS (Diluted)	-5.84	-5.83	-6.29	-8.25	-10.12	-6.70
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-489.22	-472	-421	-519	-496.59	-411.79
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-4.87	-4.79	-4.65	-7.06	-7.10	-6.07
Gross Margin	83.08%	83.80%	86.25%	89.63%	92.21%	95.44%
Operating Margin	-73.64%	-79.49%	-95.71%	-131.11%	-178.60%	-108.63%
Profit Margin	-81.70%	-85.44%	-101.61%	-139.86%	-194.70%	-129.20%
FCF Margin	-68.21%	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%
EBITDA	-495.17	-500	-500	-543	-630.7	-368.5
EBITDA Margin	-69.04%	-74.29%	-89.29%	-125.11%	-173.59%	-104.86%
EBIT	-528.17	-535	-536	-569	-648.92	-381.74
EBIT Margin	-73.64%	-79.49%	-95.71%	-131.11%	-178.60%	-108.63%
Effective Tax Rate	-0.64%	-0.70%	-0.35%	0.33%	-0.81%	-0.23%

SEC Filings: 10-K · 10-Q